Pavel Petukhov resumes & CV records
Resumes
Pavel A Petukhov, 555023 Coneflower Dr, Naperville, IL 60564
Pavel Petukhov Phones & Addresses
5023 Coneflower Dr, Naperville, IL 60564 773-5622971
Sioux Falls, SD
Oak Park, IL
Rockville, MD
Washington, DC
Eugene, OR
Gaithersburg, MD
Willeys, IL
Arlington, VA
Princeton, NJ
Social networks
Pavel A Petukhov
Linkedin
Mentions for Pavel A Petukhov
Publications & IP owners
Us Patents
Histone Deacetylase Inhibitors And Methods Of Use Thereof
US Patent:
8222451, Jul 17, 2012
Filed:
Oct 25, 2010
Appl. No.:
12/911145
Inventors:
Alan P. Kozikowski - Chicago IL, US
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Rockville MD, US
Pavel A. Petukhov - Naperville IL, US
Bin Chen - Chicago IL, US
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Rockville MD, US
Pavel A. Petukhov - Naperville IL, US
Bin Chen - Chicago IL, US
Assignee:
Georgetown University - Washington DC
International Classification:
C07C 275/04
C07C 275/22
A61K 31/155
A61K 31/16
C07C 275/22
A61K 31/155
A61K 31/16
US Classification:
564 32, 564 48, 514598, 514595
Abstract:
The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.
Histone Deacetylase Inhibitors And Methods Of Use Thereof
US Patent:
2005001, Jan 20, 2005
Filed:
Jul 7, 2003
Appl. No.:
10/614498
Inventors:
Alan Kozikowski - Arlington VA, US
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Rockville MD, US
Pavel Petukhov - Rockville MD, US
Bin Chen - Arlington VA, US
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Rockville MD, US
Pavel Petukhov - Rockville MD, US
Bin Chen - Arlington VA, US
International Classification:
A61K031/19
C07C259/04
C07C259/04
US Classification:
514575000, 514357000, 514408000, 562621000
Abstract:
The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.
Isoform Selective Hdac Inhibitors
US Patent:
2010019, Aug 5, 2010
Filed:
Aug 2, 2007
Appl. No.:
12/375348
Inventors:
Alan P. Kozikowski - Chicago IL, US
Mira Jung - Rockville MD, US
Anatoly Dritschilo - Bethesda MD, US
Arsen Gaysin - Berwyn IL, US
Pavel A. Petukhov - Naperville IL, US
Werner Tueckmantel - Yorktown Heights NY, US
Hongbin Yuan - San Diego CA, US
Mira Jung - Rockville MD, US
Anatoly Dritschilo - Bethesda MD, US
Arsen Gaysin - Berwyn IL, US
Pavel A. Petukhov - Naperville IL, US
Werner Tueckmantel - Yorktown Heights NY, US
Hongbin Yuan - San Diego CA, US
Assignee:
Georgetown University - Washington DC
International Classification:
A61K 31/426
C07C 237/00
C07D 277/20
A61K 31/16
A61K 31/4706
A61K 33/40
A61K 31/439
A61K 31/47
A61K 31/505
A61K 31/65
A61K 31/7052
A61P 33/06
C07C 237/00
C07D 277/20
A61K 31/16
A61K 31/4706
A61K 33/40
A61K 31/439
A61K 31/47
A61K 31/505
A61K 31/65
A61K 31/7052
A61P 33/06
US Classification:
424613, 564153, 564155, 564154, 548195, 514616, 514371, 514313, 514305, 514314, 514275, 514154, 514 29
Abstract:
One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising an HDAC inhibitor of the invention; and kits comprising a an HDAC inhibitor of the invention.
Histone Deacetylase Inhibitors And Methods Of Use Thereof
US Patent:
2013006, Mar 14, 2013
Filed:
Jul 17, 2012
Appl. No.:
13/551086
Inventors:
Alan P. Kozikowski - Chicago IL, US
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Rockville MD, US
Pavel A. Petukhov - Naperville IL, US
Bin Chen - Chicago IL, US
Anatoly Dritschilo - Bethesda MD, US
Mira Jung - Rockville MD, US
Pavel A. Petukhov - Naperville IL, US
Bin Chen - Chicago IL, US
Assignee:
Georgetown University - Washington DC
International Classification:
A61K 31/16
A61K 31/17
C07C 275/40
C07C 275/26
A61P 25/00
C07C 233/06
C07C 233/07
A61K 31/167
A61P 35/00
C07C 275/24
C07C 275/28
A61K 31/17
C07C 275/40
C07C 275/26
A61P 25/00
C07C 233/06
C07C 233/07
A61K 31/167
A61P 35/00
C07C 275/24
C07C 275/28
US Classification:
514597, 564 56, 514595, 564 50, 564 57, 514588, 564 48, 514596, 564152, 514616, 564153
Abstract:
The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.
Photoreactive Benzamide Probes For Histone Deacetylase 2
US Patent:
2014037, Dec 18, 2014
Filed:
Jun 18, 2014
Appl. No.:
14/308094
Inventors:
- Urbana IL, US
Pavel Petukhov - Chicago IL, US
Pavel Petukhov - Chicago IL, US
International Classification:
C07D 333/24
C07C 245/24
C07C 245/24
US Classification:
549 77, 552 8
Abstract:
The design, modeling, synthesis, biological evaluation, and photoaffinity labeling studies of a series of photoreactive potent and selective HDACs 1 and 2 benzamide based probes are disclosed herein.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.